BioMarin Pharmaceuticals (BMRN) Misses Q4 EPS by 12c; Guides FY12 Revs Below
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $54.59 -1.44%
EPS Growth %: +1,008.3%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
PGR, OMID, ACI, More
EPS Growth %: +1,008.3%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q4 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $115.3 million.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman’s CEO Solomon says to watch political volatility around data centers
- Nebius shares fall amid AI valuation concerns
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
